Novel approach shows promise against UTIs

A story about Jim Janetka’s research on antibiotic-sparing therapeutics, prompted by his new paper in J Med Chem, has just published in The Record. His research group has developed small molecules that prevent bacteria from sticking to the bladder wall, halting development of urinary tract infections in mice.
The technology is the basis of his startup company, Fimbrion Therapeutics, who have recently entered into a collaboration with GlaxoSmithKline to further develop the lead compounds for human clinical trials.

You can view the story here (wustl.edu).